Serum β-Defensin-2 Levels and Their Relationship with the Clinical Course and Prognosis in Patients with Crimean-Congo Hemorrhagic Fever

Medical Principles and Practice

Volumn 25, Issue 2, 2016, Pages 163-168

  Aksoy, Osman ^a   Parlak, Emine ^b   Parlak, Mehmet ^b   Aksoy, Hülya ^b  

^a Ballkll Göl State Hospital   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

Author keywords

Antimicrobial peptide; Crimean Congo hemorrhagic fever; Hemophagocytic syndrome; Defensin 2

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BETA DEFENSIN 2; BETA DEFENSIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STUDENT T TEST; BLOOD; CASE CONTROL STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

BETA-DEFENSINS; BIOMARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MALE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84958116423     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000442177     Document Type: Article

References (22)

1. Ergonul O: Crimean-Congo haemorrhagic fever. Lancet Infect Dis 2006; 6: 203-214.
2. Whitehouse CA: Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64: 145-160.
3. Akinci E, Bodur H, Leblebicioglu H: Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2013; 13: 429-437.
4. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, et al: Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010; 135: 1-11.
5. Swanepoel R, Gill DE, Shepherd AJ, et al: The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11: 794-800.
6. Ergonul O, Celikbas A, Baykam N, et al: Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect 2006; 12: 551-554.
7. Ozkurt Z, Kiki I, Erol S, et al: Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52: 207-215.
8. Jamil B, Hasan RS, Sarwari AR, et al: Crimean-Congo hemorrhagic fever: experience at a tertiary care hospital in Karachi, Pakistan. Trans R Soc Trop Med Hyg 2005; 99: 577-584.
9. Ergonul O: Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012; 2: 215-220.
10. Bakir M, Ugurlu M, Dokuzoguz B, et al: Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005; 54: 385-389.
11. De Smet K, Contreras R: Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005; 47: 13337-13347.
12. Meyer-Hoffert U, Schroder JM, Schwarz T, et al: Increased expression of human beta-defensin 3 in molluscum contagiosum. Clin Exp Dermatol 2010; 35: 190-192.
13. Gong TX, Jiang Y, Wang YL, et al: Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry. Arch Virol 2010; 155: 491-498.
14. Proud D, Sanders SP, Wiehler S: Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. J Immunol 2004; 172: 4637-4645.
15. Mammen EF: Disseminated intravascular coagulation. Clin Lab Sci 2000; 13: 239-245.
16. Ergonul O, Tuncbilek S, Baykam N, et al: Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis 2006; 193: 941-944.
17. Chen JP, Cosgriff TM: Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis 2000; 11: 461-483.
18. Burt FJ, Swanepoel R, Shieh WJ, et al: Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 1997; 121: 839-845.
19. Ardalan MR, Tubbs RS, Chinikar S, et al: Crimean-Congo hemorrhagic fever presenting as thrombotic microangiopathy and acute renal failure. Nephrol Dial Transplant 2006; 21: 2304-2307.
20. Shepherd AJ, Swanepoel R, Leman PA: Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 4: 801-806.
21. Geisbert TW, Hensley LE, Larsen T, et al: Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163: 2347-2370.
22. Ju SM, Goh AR, Kwon DJ, et al: Extracellular HIV-1 Tat induces human beta-defensin-2 production via NF-kappaB/AP-1 dependent pathways in human B cells. Mol Cells 2012; 33: 335-341.